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Abstract
Chronic post-hypoxic myoclonus, also known as Lance-Adams syndrome (LAS) 
is a neurological complication characterized by uncontrolled myoclonic jerks 
following cardiac arrest. In this article, clinical manifestation and symptomatic 
treatment options are discussed especially concerning the rationale of use of 
levatiracetam in patients with Lance-Adams syndrome. Clinical presentation 
is action myoclonus associated with cerebellar ataxia, postural imbalance, and 
very mild intellectual deficit. 
An 18-year-old female patient was admitted to our intensive care unit in a 
coma. She had a cardiorespiratory arrest after a splenectomy in a local hospital. 
Then, myoclonic movements were continuously observed over the entire body, 
including the face.
On day 14 of hospitalization, we started levatiracetam 1000 mg daily. The 
frequency of convulsion movements was reduced. The patient level of 
consciousness was 15 on the Glasgow coma scale (GCS) on the Mini-Mental 
State Examination (MMSE) score was 23 out of 30. She was later transferred to 
the rehabilitation department.
Vigilance is required to ensure early diagnosis and timely intervention for the 
myoclonic jerks.
We would like to emphasize that LAS should be considered in patients with the 
myoclonic jerks following cardiac arrest and that levatiracetam therapy may be 
useful as treatment.
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Post-hypoxic myoclonus (PHM) is a neurological complication characterized by 
uncontrolled myoclonic jerks following cardiac arrest. Two types of PHM, acute 
and chronic, occur in patients with hypoxic injury of the brain. Chronic PHM, also 
known as Lance-Adams syndrome (LAS), first described in 1963, is a condition 
characterized by development of chronic post-hypoxic action myoclonus due to a 
temporary lack of or inadequate brain oxygen supply (1-2). Clinical presentation 
is action myoclonus associated with cerebellar ataxia, postural imbalance, and 
very mild intellectual deficit (3). In this report, we present a case of Lance-Adams 
syndrome and discuss its main clinical manifestation and symptomatic treatment 
options of this rare disease in the light of the relevant literature. 
Case Study
An 18-year-old female patient was admitted to our intensive care unit in a 
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LAS (5). Although, the pathophysiology of LAS has 
not been clearly defined, the prognosis is known to be 
quite good (4). On day 3 of hospitalization, our patient 
from the case- study developed a myoclonic jerk after 
cardiorespiratory arrest. Generalized myoclonic jerks 
were aggravated by voluntary movements, sounds, and 
touches, but disappeared with a relaxation of the body 
and limbs or during a sleep. She had mild cognitive 
deficit accompanied by dysmetria and dysarthria. These 
clinical features fulfilled the criteria for the diagnosis 
of Lance-Adams-type myoclonus. The myoclonus 
in LAS has no consistent correlation with EEG 
abnormalities. A combination of medications based 
on the neurotransmitter hypotheses is often needed to 
obtain appropriate control of symptoms. Frucht and Fahn 
reviewed more than 100 patients with LAS, they found 
that clonazepam, valproate, and piracetam were effective 
in treating approximately 50% of these cases(6). The 
patient underwent consecutive trials of sodium valproate 
to 1,500 mg daily and clonazepam to 3 mg daily without 
efficacy. We began with 1000 mg levatiracetam daily 
and the myoclonic jerks terminated on the 8th day of 
treatment. Clonazepam and valproate were gradually 
discontinued. Further studies to clarify the pathogenesis 
of LAS are important to find novel therapeutic methods. 
coma. The past medical history of the patient was 
normal without any additional problems. She had a 
cardiorespiratory arrest after a splenectomy in a local 
hospital. On day 3 of hospitalization, she developed 
a generalized seizure in the intensive care unit after 
discontinuing an intravenous infusion of midazolam (5 
mg per hour) and fentanyl (100 μg). Then, myoclonic 
movements were continuously observed over the entire 
body, including the face. Cranial computed tomography 
(CT) scans, T1 and T2 weighted MR imaging, and 
DW imaging showed no abnormality (Fig 1). Seven 
days later, the patient regained her consciousness and 
had no hemiparesis or aphasia. Sodium valproate and 
clonazepam were started; however, the myoclonic jerks 
were not controlled after increasing the dose of sodium 
valproate to 1,500 mg and clonazepam to 3 mg daily. 
AN electroencephalography (EEG) performed at this 
time demonstrated frequent myoclonic polyspikes 
but did not confirm myoclonic status (Fig 2). She 
continued to have a moderate generalized myoclonus 
in the face, trunk, and limbs accompanied by dysmetria, 
dysarthria, and ataxia. Generalized myoclonic jerks 
were aggravated by voluntary movements, sounds, 
and touches, but disappeared with a relaxation of the 
body or during a sleep. On day 14 of hospitalization, 
we started levatiracetam 1000 mg daily. The frequency 
of convulsion movements was reduced. Her level of 
consciousness was 15 on the Glasgow coma scale 
(GCS). Her Mini-Mental State Examination (MMSE) 
score was 23 out of 30. On day 27 of hospitalization, she 
was transferred to the rehabilitation department.
Discussion 
Lance-Adams syndrome (LAS) was first described in 
the 1960s by Lance and Adams. Clinical presentation 
is action myoclonus associated with cerebellar ataxia, 
postural imbalance, and very mild intellectual deficit. 
Myoclonic jerks are specifically triggered by action 
and tactile stimulation. They usually disappear with 
relaxation of the body. Diagnostic imaging tests such 
as CT or MRI of the brain are not helpful to make a 
diagnosis of LAS. Neuroimaging, such as brain single-
photon emission computed tomography (SPECT) or 
brain positron emission tomography (PET) has recently 
shown anatomical and pathophysiological basis of 
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relaxation of the body and limbs or during a sleep. She had mild cognitive deficit 
accompanied by dysmetria and dysarthria. These clinical features fulfilled the criteria for the 
diagnosis of Lance-Adams-type myoclonus. The myoclonus in LAS has no consistent 
correlation with EEG abnormalities. A combination of medications based on the 
neurotr nsmitter hypotheses is often needed to obtain appr priate control of symptoms. 
Frucht and Fahn reviewed more than 100 patients with LAS, they found that clonazepam, 
valproate, and piracetam were effective in treating approximately 50% of these cases (6). The 
patient underwent consecutive trials of sodium valproate to 1,500 mg daily and clonazepam to 
3 mg daily without efficacy. We began with 1000 mg levatiracetam daily and the myoclonic 
jerks terminated on the 8th day of treatment. Clonazepam and valproate were gradually 
discontinued. Further studies to clarify the pathogenesis of LAS are important to find novel 
therapeutic methods. The neurotra smitters related to LAS are known to be serotonin and 
gam a-aminobutyric acid (GABA). The l ss of serotonin within the inferior olive nucleus 
has been thought to play some role and GABA may interact with the serotonin system to 
suppress post-hypoxic myoclonus (7).  
Vigilance is required to ensure early diagnosis and timely intervention for the myoclonic 
jerks. In conclusion, we would like to emphasize that LAS should be considered in patients 
with the myoclonic jerks following cardiac arrest and that levatiracetam therapy may be 
useful as treatment. 
 
Fig 1 : MRI showed no cerebral abnormality. 
 
The neurotransmitters related to LAS are known to be 
serotonin and gamma-aminobutyric acid (GABA). The 
loss of serotonin within the inferior olive nucleus has 
Fig 1. MRI showed no cerebral abnormality.
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been thought to play some role and GABA may interact 
with the serotonin system to suppress post-hypoxic 
myoclonus (7). 
Vigilance is required to ensure early diagnosis and 
timely intervention for the myoclonic jerks.
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In conclusion, we would like to emphasize that LAS 
should be considered in patients with the myoclonic 
jerks following cardiac arrest and that levatiracetam 
therapy may be useful as treatment.
 
Fig 2. EEG showed generalized paroxysmal epileptic activity.
